Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

TAVR valve for AR , a recent Edwards acquisition, delivers long-term value
The J-Valve System is associated with positive 10-year outcomes for patients with severe AR, according to new research out of China. It also performs well in patients with severe AS.
SAVR linked to ‘excellent’ long-term survival for patients with bicuspid aortic valves
Survival rates are high for both men and women presenting with BAV disease, according to a new analysis of nearly 28,000 SAVR patients.
Medtronic SVP Nina Goodheart to retire after nearly 20 years in cardiovascular care
Nina Goodheart, the president of Medtronic’s structural heart and aortic business, has announced her retirement.
Key trends in transcatheter tricuspid valve repair and replacement
The interventional treatment of tricuspid valve disease has evolved in recent years thanks to new research and critical FDA approvals. Cardiologist Ryan Kaple, MD, reviewed this trend for a new video interview.
Pioneer heart surgeon Vinay Badhwar elected STS president
Badhwar is a longtime STS member and world leader in robotic technologies. In fact, he and his team recently launched a 40-part video series to help teach other clinicians about robotic-assisted cardiac surgery.

TAVR valve for AR , a recent Edwards acquisition, delivers long-term value

The J-Valve System is associated with positive 10-year outcomes for patients with severe AR, according to new research out of China. It also performs well in patients with severe AS.

SAVR linked to ‘excellent’ long-term survival for patients with bicuspid aortic valves

Survival rates are high for both men and women presenting with BAV disease, according to a new analysis of nearly 28,000 SAVR patients.

Medtronic SVP Nina Goodheart to retire after nearly 20 years in cardiovascular care

Nina Goodheart, the president of Medtronic’s structural heart and aortic business, has announced her retirement.

Transcatheter treatment of tricuspid valve disease has rapidly evolved over the past two years, giving physicians new tools to address a condition long considered under treated due to limited procedural options and complex anatomy. Ryan K. Kaple, MD, FACC, FSCAI, director of the structural and congenital heart program at Hackensack University Medical Center, spoke top Cardiovascular Business about recent advances and his center's real-world experience.

Key trends in transcatheter tricuspid valve repair and replacement

The interventional treatment of tricuspid valve disease has evolved in recent years thanks to new research and critical FDA approvals. Cardiologist Ryan Kaple, MD, reviewed this trend for a new video interview.

Pioneer heart surgeon Vinay Badhwar elected STS president

Badhwar is a longtime STS member and world leader in robotic technologies. In fact, he and his team recently launched a 40-part video series to help teach other clinicians about robotic-assisted cardiac surgery.

Valcare Medical’s Amend Transseptal System for mitral regurgitation

Interventional cardiologists implant new-look heart device for first time in US

The Amend device from Valcare Medical has a closed ring shape similar to the annuloplasty rings used to treat MR during open-heart surgeries. These early patients will be followed for a total of five years.

HighLife Transcatheter Mitral Valve Replacement (TMVR) System

TMVR device with valve-in-ring design gains key approval

HighLife's new-look TMVR technology was designed to treat a wide range of patients. The two-part implant process includes a ring and a valve that centers itself inside that ring.

old woman or doctor shaking hands with patient

Patients with paradoxical low-flow, low gradient AS linked to higher mortality rate after TAVR

Patients with this specific subtype of severe aortic stenosis, which can sometimes be challenging to diagnose, face a number of additional risks.